Hematopoetic progenitor cell trafficking is a multifactorial process that involves adhesion molecules, chemokines and cytokines. Mechanisms controlling migration across bone marrow endothelium most likely play key roles in hematopoitic progenitor cell mobilization and homing. Using an in vitro assay of transendothelial migration, we have shown that only few CD34+ progenitor cell migrate spontaneously. A positive transendothelial gradient of the chemokine stromal cell-derived factor-1 (SDF-1), which is constitutively released by bone marrow stromal cells, substantially increases progenitor cell migration. By immunofluorescence analysis, we demonstrate that chemokineinduced migration of CD34+ progenitors is independent from lineage committment. Both immature (CD24+/CD38−, CD34+/Thy-1+) and more committed (CD24+/CD38+, CD34+/Thy-1−) progenitor cells express the receptor for SDF-1, the chemokine receptor CXCR-4.
Hematopoetic progenitor cell trafficking is a multifactorial process that involves adhesion molecules, chemokines and cytokines. Mechanisms controlling migration across bone marrow endothelium most likely play key roles in hematopoitic progenitor cell mobilization and homing. Using an in vitro assay of transendothelial migration, we have shown that only few CD34+ progenitor cell migrate spontaneously. A positive transendothelial gradient of the chemokine stromal cell-derived factor-1 (SDF-1), which is constitutively released by bone marrow stromal cells, substantially increases progenitor cell migration. By immunofluorescence analysis, we demonstrate that chemokineinduced migration of CD34+ progenitors is independent from lineage committment. Both immature (CD24+/CD38−, CD34+/Thy-1+) and more committed (CD24+/CD38+, CD34+/Thy-1−) progenitor cells express the receptor for SDF-1, the chemokine receptor CXCR-4.
Cell surface and mRNA expression of CXCR-4 is low on circulating normal CD34+ progenitors and CD34+ AML blasts compared to bone marrow-derived cells, indicating that downmodulation of chemokine receptors supports the egress of normal and malignant CD34+ hematopoietic cells from the bone marrow into the peripheral blood. This concept is supported by the finding that the expression level of CXCR-4 correlates with the functional response (transendothelial migration) to SDF-1. However, also in circulating CD34+ progenitor cells and CD34+ AML blasts SDF-1 induces a rapid flux of intracellular free calcium which is reduced by a blocking CXCR-4 antibody, demonstrating that also weakly expressed CXCR-4 is functionally active.
Using blocking monoclonal antibodies, we show that also chemokine-supported transendothelial progenitor cell migration is modulated by adhesion molecules of the integrin family and their endothelial ligands, and particularly by the endothelial adhesion molecule E-selectin. High mRNA expression of the E-selectin ligand-1 (ESL-1) in hematopoietic progenitors supports the concept that E-selectin and its ligand(s) play an important role for progenitor cell trafficking. In addition, hematopoietic progenitor cells express enzymes required for glycosylation of selectin ligands. Particularly, circulating hematopoietic progenitor cells express specific fucosyltransferases important for fucosylation and functional activity of E-selectin ligands.
In addition to modulation of chemokine-induced progenitor cell migration by adhesion molecules, also engagement S24 of chemokine receptors modulates avidity of adhesion molecules. Particularly, stimulation of CD34+ progenitors with the chemokine SDF-1 results in a rapid increase of adhesion to the endothelial adhesion molecule VCAM, which is inhibited by antibodies to the ligand VLA-4 expressed by CD34+ hematopoietic progenitor cells.
We conclude that reciprocal interaction of adhesion molecules (integrins, selectins, selectin ligands) and chemokines (e.g. SDF-1) control transendothelial migration of hematopoietic progenitor cells during mobilization and homing. Thus, growth factor-induced modulation of expression and avidity of several chemokine receptors and adhesion molecules may synergistically result in progenitor cell mobilization. The ␤1 integrin very late antigen-4 (VLA-4) plays a central role in mobilization and homing of CD34+ hematopoietic stem cells since treatment of primates and mice with VLA-4 specific monoclonal antibodies resulted in peripherilization of progenitor cells. In this study, we examined antisense oligonucleotides (ODN) directed against the mRNA of the ␣4-chain of VLA-4 as a new modality to mobilize CD34+ hematopoietic progenitor cells. Antisense ODN were transfected into immunogenetically enriched CD34+ cells from leukapheresis products of cancer patients after G-CSF-supported cytotoxic chemotherapy using the cationic lipid DOTAP. Consistent with data obtained by Northern and Western blot analysis, a significant antisense mediated downregulation of the VLA-4 surface expression of 29% (SD: 13.1%; p Ͻ 0.01) was measured after 4 days in suspension culture as assessed by dual-colour immunofluorescence analysis. Downregulation of VLA-4 expression on CD34+ cells resulted in an inhibition of the colony-forming capacity in a semi-solid culture assay of 39% (SD: 12.8%; p Ͻ0.01) and in a significant inhibition of adhesion to IL-1␤-stimulated cells of 29% (SD: 19%; p Ͻ 0.05). This indicates a functional role of VLA-4 not only for adhesion but also for proliferation of CD34+ cells. Using Dexter-type long term bone marrow cultures (LTBMC) as in vitro model for stem cell mobilization, a 29-fold increase of colony-forming units in the non-adherent cell fraction of antisense-treated cultures was found. This was reflected by a proportion of 0.77% (SD: 0.69%; p Ͻ 0.05) cells expressing CD34 in antisense ODN-treated LTBMC, while their proportion was 0.18% (SD: 0.20% in LTBMC treated with control ODN) indicating a mobilization of progenitor cells from bone marrowstroma in vitro. Preliminary results from systemic administration of ␣4-specific antisense ODN in mice showed an increased number of peripheral mononuclear cells expressing the stem cell antigen in comparison with control ODN-treated mice. In conclusion, VLA-4-directed antisense ODN are useful tools for studies on function of VLA-4 on CD34+ cells. In addition, these results could provide the basis for a novel clinical application of antisense ODN to improve progenitor cell mobilization, particularly for patients or healthy donors with inefficient peripheralization of CD34+ cells for autologous or allogeneic transplantation.
S12f: Determination of Cytokeratin Expressing Cells in Blood, Bone Marrow and Blood Progenitor Cell Products
W. Gebauer, E. Fallgren Gebauer, I. Barklage, F. Schunter, Red Cross, Oldenburg, Germany
Blood progenitor cell (bpc) products for autologous transplantation of patients after high dose chemotherapy of malignant diseases is a growing field of interest in blood banks. Many patients suffering from epithelial malignancies get tumor cells reinfused among hematopoetic progenitor cells after high dose chemotherapy. Quantitation of malignant contamination is demonstrated. BPC products, mononuclear cell fractions after density gradient separation and unfractionated blood were analysed. Flow cytometry and immunocytochemical techniques were used with and without enrichment of epithelial cells prior to immunological analysis. Cell populations from patients treated in Oldenburg from 1992 until 1999 for germ cell tumors, breast cancer and other malignancies were characterized.
In anticoagulated blood, bone marrow or bpc apheresis products of patients treated for breast cancer in 25%, 21% and 7% of the patients cells expressing epithelial antigens were detected, respectively.
Enrichment followed by immunocytochemical detection of cytokeratin is demonstrated as an efficient method for determination of malignant cells of epithelial origin among blood cells. To determine the influence on apheresis timing on CD34+ cell yield, subpopulation and tumor-cell contamination, 48 women with breast cancer were stimulated in a prospective, but non-randomized study with 2 × 5 g/kg G-S25 CSF s.c. and apheresis was started either on day 4 (n = 24) or day 5 (n = 24). Patients and methods: 48 women with breast cancer (stage II/III: n = 30; stage IV: n = 12; inflammatory: n = 6) and a median age of 44 years were well balanced between the two groups. In group I apheresis was started on day 4 and additionally performed on day 5 after G-CSF stimulation, and in group II apheresis was started on day 5. CD34+ cell count and CD34+ cell-subpopulation were per formed according to international criteria. Tumor-cell contamination was detected by immuncytology. The median CD34+ cell harvest on day 4 was 3.3 × 10 6 /kg body weight (r.:0.5-12.8) and 6.0 × 10 6 /kg body weight (r.: 0.3 − 30) for pts starting on day 5 (n.s.). No differences were observed between the CD34+ cell subpopulation CD34+/CD38− (10.5/ vs 10.5%) and CD34+/Thy-1+ (1.5% vs 1.8%). The CD34+ harvest from consecutive collecting on day 4 and 5 was nearly identical to the harvest on starting day 5 (6.4 vs 6.0 × 10 6 /kg). Conclusion: Collecting CD34+ progenitor cells after stimulation with G-GSF alone on day 5 results in a significantly higher cell yield than starting collecting on day 4. No differences with respect to tumor-cell contamination and CD34+ cell-subpopulation was observed.
